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+ regulatory T (Treg) cells play a pivotal role in the maintenance of immune homeostasis, where the X-linked master transcription factor forkhead box P3 (FOXP3) determines Treg cell development and function. Genetic deficiency of foxp3 induces dysfunction of Treg cells and immuno-dysregulation, polyendocrinopathy, enteropathy, and X-linked syndrome in humans. Functionally deficient Treg cells or the development of exTreg cells positively correlate with autoimmune diseases, such as systemic lupus erythematosus (SLE), multiple sclerosis (MS), and ankylosing spondylitis (AS). In general, females are more susceptible to SLE and MS but less susceptible to AS, where the expression of FOXP3 and its protein complex are perturbed by multiple factors, including hormonal fluctuations, inflammatory cytokines, and danger signals. Therefore, it is critical to explore the potential molecular mechanisms involved and these differences linked to gender. Here, we review recent findings on the regulation of FOXP3 activity in Treg cells and also discuss gender difference in the determination of Treg cell function in autoimmune diseases.
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Regulatory T (Treg) cells, via their immune suppressive capability, play an indispensable role in maintaining immune homeostasis and preventing autoimmunity induced by excessive, misdirected, or unnecessary immune activation. Surface-expressed cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) mediates suppression of target cells by cell-cell contact (1) (2) (3) (4) . Treg cells can also reduce T cell activation and proliferation through CD39-CD73-mediated production of metabolic adenosine (5) . Meanwhile, Treg cells have been shown to harbor cytotoxic capacity and induce target cell apoptosis through release of granzymes A/B and perforin (4) . Anti-inflammatory cytokines that are secreted by Treg cells can also induce immune tolerance (6, 7) .
Under pathogenic conditions, such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS), Treg cells exhibit plasticity to some extent and may mimic T helper-like phenotypes. Recent studies have provided insight into the understanding of the stability and activity of forkhead box P3 (FOXP3) in Treg cells regulated by T cell receptor (TCR) signaling, inflammatory cytokines, and danger signals. Here, we discuss the cellular and molecular mechanisms underlying FOXP3-mediated regulation of Treg cells and also the possible effect that gender difference has on Treg cells and autoimmune diseases. 
FOXP3 Mutations and Autoimmunity
The transcription factor FOXP3 belongs to the fork-winged helix family and is encoded by the foxp3 gene on the X chromosome. Genetic deletion of the foxp3 gene and the loss of Treg cells promote the development of autoimmune and inflammatory syndromes (8) (9) (10) . Ectopic expression of FOXP3 in CD4
+ CD25 − T cells may endow CD4 + CD25 − T cells with Treg-like suppressive capability to prevent inflammatory bowel disease (IBD) and autoimmune gastritis (9) . FOXP3-deficient Treg cells have decreased levels of Treg cell signature genes, including ctla4, ebi3, il10, and entpd1, and acquire the expression of T effector cytokine genes such as ifng, tnfα, il4, and il17 (11) (12) (13) (14) . A frame-shift mutation in the foxp3 gene locus in scurfy mice results in the expression of FOXP3 protein lacking its forkhead domain (15). Many other loss-of-function mutations at the foxp3 gene locus have also been identified in patients with immune-dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance syndrome (IPEX) (16, 17) . Genetic mutations of the foxp3 gene are always accompanied by the lack of the functional Treg cells, therefore resulting in the development of diverse arrays of autoimmune diseases. A compilation of studies describing the role of genetic mutants of the foxp3 gene in autoimmune diseases is shown in Table 1 . In the thymus, the development of tTreg cells requires extracellular signals, including TCR-mediated self-antigen recognition, 
FOXP3 and Treg Cell Development
FOXP3
+ T cells were still detectable, but drastically reduced in il2
, il2rβ −/− and γc −/− mice (47). In the thymus, TGF-β signals prevent tTreg cell apoptosis. Conditional deletion of the TGF-β type I receptor (Tgfbr1) gene in T cells causes tTreg cells in the thymus to become more susceptible to apoptosis during negative selection, while bim ablation may restore TGF-β signal deficiency (48) .
Recent studies showed that FOXP3 expression alone was not sufficient for Treg lineage commitment. The demethylation status of a Treg-specific demethylation region (TSDR) in the foxp3 promoter plays an essential role in Treg lineage maintenance where the demethylation of the TSDR correlates with stable Treg cell phenotype. Gene expression profile analysis in FOXP3-non-expressing T cells that lacked methylation of the TSDR, and FOXP3-expressing T cells that retained methylation of the TSDR, showed higher similarity to tTreg cells in the former in gene expression but lack of repression in the expression of il2, ifng, and zap70; however, the latter cells exhibited normal il2, ifng, and zap70 repression but upregulated a set of genes that were The regulation of Treg cells Frontiers in Immunology | www.frontiersin.org not expressed in tTreg cells. These results indicated that FOXP3 expression and the demethylation of the TSDR are both vital to establish Treg lineage commitment, but neither of them alone is sufficient (49) .
In the periphery, combined TCR, TGF-β, and IL-2 signals polarize naïve CD4 + T cells into pTreg cells. These pTreg cells possess similar suppressive capacities as tTreg cells in vitro and in vivo (50, 51) . Both tTreg and pTreg cells express FOXP3, CD25, CTLA-4, GITR, CD39, and CD73, along with low levels of IL-7Rα (CD127) (52) . Current studies indicate that tTreg and pTreg cells play differential roles in different inflamed tissues. pTreg cells are more functional for maintaining mucosal tolerance, while tTreg cells are for maintaining immune tolerance. Due to the lack of specific lineage markers to distinguish between tTreg and pTreg cells in humans, it remains difficult to illustrate the different functions of tTreg and pTreg cells. Helios has been identified as a marker for tTreg cells (53) . However, tTreg subsets have been found to contain both FOXP3
+
Helios
+ and FOXP3 + Helios − subpopulations, suggesting that Helios is not a specific marker for tTreg/pTreg cells (54) . Other studies have identified Neuropilin 1 (NRP1) specifically and highly expressed on tTreg cells but not pTreg cells (55) , and glycoprotein A repetitions predominant (GARP) expressed on activated human tTreg cells but not TGFβ-induced iTreg cells (56) , but subsequent reports found that NRP1 low pTreg cells could be converted into NRP1 hi pTreg cells under inflammatory environments (57) . Therefore, other surface markers need to be discovered for distinguishing between tTreg and pTreg cells.
The Stability of Treg Cells
As Treg cells have been identified as a specific cell population possessing suppressive capacity to maintain immune 
The Regulation of FOXP3 expression
The significance of FOXP3 to Treg development and stability is well documented. Direct evidence that has shown FOXP3 protein to be important for Treg function has been provided by experiments that inserted a gene cassette co-expressing luciferase and enhanced green fluorescent protein (eGFP) into the 3′-untranslated region (UTR) of the endogenous foxp3 locus of C57BL/6 mice. This lead to FOXP3 mRNA instability, a 90% decrease of FOXP3 protein expression, and as a consequence these mice succumbed to aggressive lymphoproliferative autoimmune syndrome, indicating that Treg cell function directly correlates with the amount of FOXP3 protein expressed (12). Observations like this make it imperative to explore the molecular mechanisms regulating FOXP3 expression (Figure 2 ).
epigenetic Control of FOXP3 expression
Epigenetic modifications of the foxp3 gene at its regulatory regions regulate chromatin accessibility for transcription factors and other transcriptional regulators to control FOXP3 expression and Treg cell stability. Chromatin immunoprecipitation (ChIP) assays have revealed higher levels of acetylated histone H4 within the foxp3 promoter in activated Treg cells (68) . Treatment with histone deacetylase inhibitors leads to an increased expression of FOXP3 and percentages of FOXP3 + Treg cells in vivo (69) , implying that the upregulation of FOXP3 expression is controlled by histone modifications. Both H3K4me2 and H3K4me3 are induced at the transcriptional start sites and regulatory regions at the foxp3 gene locus in both tTreg and iTreg cells upon TCR stimulation (70) . Inhibition of H3K4me3 at the foxp3 gene locus impairs TGFβ-induced FOXP3 expression (71) .
The methylation status of CpG islands within the foxp3 promoter and regulatory elements also regulates the expression of FOXP3 in Treg cells. Through bisulfite sequencing, investigators have identified a CpG-rich region upstream of exon-1 of the foxp3 gene locus and this region is highly conserved between human and mice. This evolutionarily conserved region is highly demethylated in tTreg cells, incompletely demethylated in iTreg cells, and methylated in naïve CD4 + CD25 − T cells. This demethylated region is correlated with stable FOXP3 expression and closely associated with modified histones, including acetylated and trimethylated histone H3 but not acetylated histone H4 (72) . Genome-wide DNA methylation pattern analysis confirmed specific CpG methylation patterns at other Treg cell-associated gene regions, including il2ra, ctla4, tnfrsf18, ikzf4, and ikzf2 (49) . Inhibition of DNA methylation by 5-aza-2′-deoxycytidine or deleting DNA methyltransferase-1 (DNMT-1) induces strong and stable expression of FOXP3 under TCR stimulation even in the absence of TGF-β, which further confirms that the TSDR methylation status of the foxp3 gene locus controls the expression of FOXP3 (73, 74) .
Transcriptional Regulation of FOXP3
Upon TCR activation, AP1, CREB, NFAT, c-Rel and ATF bind to the promoter of the foxp3 gene and activate its gene transcription in Treg cells (68, (75) (76) (77) (78) (79) (80) . Foxo-binding sites were also found within the foxp3 basal promoter, where deficiency of Foxo1 and Foxo3 in Treg cells causes a loss of FOXP3 expression (81) . IL-2 signaling is essential to maintain FOXP3 expression in a STAT5-dependent manner (47, 82, 83). Additionally, IL-2 may induce the expression of SMAR1 in Treg cells, while IL-6 does the opposite. SMAR1-bound STAT3 promoters can suppress its gene transcription. Deficiency of SMAR1 in Treg cells causes the upregulation of STAT3, which in turn converts Tregs into Th17-like cells and facilitates increased susceptibility to IBD (84) .
In the periphery, naïve T cells can be converted into FOXP3 + Treg cells in the presence of TGF-β. TGF-β induces the occupancy of Runx1 and Runx3 on the promoter of foxp3, but also activates SMAD3 and NFAT binding to the conserved non-coding sequence 1(CNS1) of the foxp3 gene and induces FOXP3 expression (78, (85) (86) (87) (88) (89) (90) . Thus, CNS1 is considered to be involved in the development of pTreg cells in response to TGF-β signals. In CNS1-deficient mice, FOXP3
+ Treg cells are markedly decreased in the gut-associated lymphoid tissue (GALT) and mesenteric lymph node (MLN), where TGF-β-dependent pTreg cells are generated, but not in the spleen and non-gut draining lymph nodes (91) . In addition, RA was reported to be capable of augmenting the enrichment of SMADs to CNS1 and therefore enhances FOXP3 expression (88) .
Conserved non-coding sequence 2(CNS2) was identified as a unique region containing CpG-rich islands to maintain stable (102) . Deleted in breast cancer 1 (DBC1), a subunit of the FOXP3 complex, prevents FOXP3 degradation and maintains Treg cell stability under inflammatory conditions. Functional Dbc1 −/− mice are more resistant to develop severe autoimmune disease symptoms during induction of experimental autoimmune encephalomyelitis (EAE) (103) .
The FOXP3 Protein Complex and its Modifications
The transcription factor GATA3 is highly induced in Treg cells that reside in barrier sites, including the gastrointestinal tract and skin. GATA3 is required for maintaining high levels of FOXP3 expression by binding to and promoting the activity of cis-acting elements of FOXP3. GATA3-deficient Treg cells are more prone to acquire an effector T cell phenotype and express effector cytokines in inflamed tissues (104, 105) . USP21 positively 
Post-Translational Modifications of FOXP3
The post-translational modifications of FOXP3 affect Treg differentiation, function, and phenotypic commitment through regulating FOXP3 protein stability and transcriptional activity (Figure 3) Treg suppressive activity (112) . HIF1a and PKB/Akt1-mediated FOXP3 phosphorylation also affects FOXP3 stabilization through indirectly regulating FOXP3 ubiquitination levels (113) (114) (115) (116) . The transcriptional activity of FOXP3 is also regulated by posttranslational modifications. Our previous results demonstrated that FOXP3 could associate with the histone acetyltransferase TIP60 and the class II histone deacetylases HDAC9 and HDAC7. TIP60 can acetylate FOXP3 and enhance FOXP3-mediated transcription repression of IL-2 expression through the FOXP3 N-terminal 106 to 109aa region (117) . FOXP3 can also be acetylated by P300 and affects FOXP3 stability through impairing polyubiquitination of FOXP3, thus, blocking proteasomemediated FOXP3 degradation (114, 115) .
In addition to ubiquitination and acetylation, MS analysis has revealed that multiple residues of FOXP3 could be phosphorylated. Among these, only a small number have been further investigated. In the synovial fluid of rheumatoid arthritis patients, the pro-inflammatory cytokine TNFα induces the expression and enzymatic activation of protein phosphatase 1 Ser422 of FOXP3, which negatively regulates FOXP3 binding affinity on chromatin and also Treg function. Reversing PIM1-mediated FOXP3 phosphorylation through TCR stimulation, shRNA-mediated PIM1 depletion or by using a PIM1 inhibitor could enhance Treg suppressive function (119) . Another member of the PIM kinase family named PIM2 was also reported to be able to phosphorylate multiple sites of FOXP3 at its N-terminal domain, leading to attenuated Treg suppressive function. Pim2 −/− mice show more resistance to DSS-induced colitis (117) . FOXP3 is also the target of CDK2, which phosphorylates FOXP3 at its Ser19 and Thr175 sites to negatively regulate the stability and transcriptional activity of FOXP3 (120) . Although most investigations have reported that FOXP3 is strictly expressed in Treg cells, FOXP3 can also be expressed in cancer cells and acts as a cancer repressor (121, 122) . Lck can also phosphorylate FOXP3 at Tyr342 in breast cancer cells and increase FOXP3 transcriptional repression of mmp9, skp, and vegfa, and thus suppresses cellular invasion (123) .
Treg Cells and Gender Bias in Autoimmune Diseases
Females and males process basic immune responses rather differently. In response to infection, vaccination, or trauma, females exhibit stronger inflammation for protection against infection, while this characteristic also renders females more susceptible to autoimmune diseases. The factors that contribute to these disparate immune responses between males and females are mainly X-linked, which includes hormonal differences.
Current theories related to the pathogenesis of autoimmune diseases assume that the disrupted balance between effector T cells (that cause tissue damage) and Treg cells (that suppress self-reactive cells) correlates with the pathogenesis of autoimmune diseases. The number and function of Treg cells is affected by X-linked foxp3 and hormonal fluctuations. Thus, new insight into gender differences in autoimmune disease may reveal novel therapeutic avenues.
Treg and iPeX
The foxp3 gene is localized on the X chromosome, where mutations in this gene may cause IPEX. In females, there are two X chromosomes, where one undergoes random inactivation. If the foxp3 gene on one X chromosome is mutated, this would potentially produce functionally impaired Treg cells, whereas the other gene with the wild-type foxp3 gene would generate normal Treg cells to protect females from IPEX (124) .
Treg Cells and MS
Multiple sclerosis is characterized by chronic inflammation, primary demyelination, and axonal damage. EAE is the animal model of MS. In adoptive transfer experiments, Treg cells may prevent the development of chronic EAE in recipient mice (125) (126) (127) (128) (129) (130) (131) . MS is more prevalent in females (132) . In females, the symptoms of MS have been reported to correlate with hormonal levels. When estrogen (E2) and progesterone (P4) levels decrease during menstruation, disease relapses (133, 134) ; in turn, during the third trimester of pregnancy when estrogen and progesterone levels are at its highest, the symptoms of MS regress, followed by relapse until dropping at post-partum (135, 136) . Treatment with ER ligand protected mice from the development of EAE (137, 138) . The protective effect of ER ligand was blocked in estrogen receptor-α (Esr1 −/− )-and estrogen receptor-β (Esr2 −/− )-deficient mice (138) . Both E2 and P4 have been reported to induce high numbers of Treg cells and enhance Treg function (139) (140) (141) (142) . E2 treatment increased Treg cell number and FOXP3 expression both in vitro and in vivo. In estrogen receptor-α-deficient mice, E2-induced expression of FOXP3 is abrogated (141, 143) . E2 was reported to regulate Treg function partially through increasing intracellular levels of the checkpoint inhibitor PD-1. PD-1 expression and Treg suppressive function were attenuated in ER-KO mice. E2 pretreatment could partially restore the suppressive function of Treg cells in PD-1 KO mice without affecting FOXP3 expression (144) .
Other reports have revealed how 17β-estradiol enhances Treg suppressive function via promoting TGF-β and IL-10 secretion (145). P4 may drive cord blood fetal T cells but not adult peripheral blood T cells to differentiate into FOXP3 + Treg cells. These P4-induced Treg cells exhibit a memory phenotype and better suppressive activity. Mechanistically, P4 enhances IL-2-STAT5 signaling and represses IL-6-mediated STAT3 activation by downregulating the IL-6 receptor, facilitating Treg differentiation but suppression of Th17 differentiation (139) . P4 could also suppress the mTOR pathway, and thus promote the generation of Treg cells (146) and these Treg express higher levels of ERβ compared with T-responder cells. In MS patients, Treg cells express lower levels of ERβ (147), thus implying that having Treg cells unresponsive to hormones might result in the dysregulation of immune homeostasis and contribute to the pathogenesis of MS.
Frequencies of Treg cells change during the course of pregnancy (148) . During pregnancy, elevated E2 levels at early stages are important for CD4 + CD25 + Treg cell expansion in mice and are required for embryo implantation (149) . Estrogen-treated mice and pregnant mice share similarities in increases of FOXP3 expression and Treg function (150) . E2 and P4 increase maintains the expansion of systemic and local uterine Treg cells (140) . The correlation between pregnancy-induced fluctuations in Treg cells and MS amelioration remain unclear, which might be influenced by different flow-cytometric approaches and current lack of studies.
Treg Cells and SLe
The imbalance of Th17/Treg cells usually correlates with the pathogenesis of SLE (151, 152) . For SLE, data have shown a gender bias toward prevalence in females, with the female:male ratio at almost 9:1 (132). IL-6 plays a very important role in regulating the balance between Th17 cells and Treg cells. In the presence of IL-6, naïve CD4 + T cells differentiate into Th17 cells (with TGF-β) rather than iTreg cells (153) . IL-6 together with IL-1 induces the degradation of FOXP3 and deregulates Treg cells (61) . Higher concentrations of IL-6 in sera and in urine have been detected in SLE patients; the concentration of IL-6 in SLE patient sera and urine is positively correlated with disease severity (154) (155) (156) (157) . The expression of IL-6 is upregulated by estrogens (158) and is dominant in females (159) . In mice, blocking IL-6 could significantly increase FOXP3 expression and make animals resistant to ALD-DNA-induced SLE (160) . IL-6 may affect Th17/Treg balance in males and females, and thus contributes to the prevalence of SLE in females. So far, related studies are limited and more evidence is required to further characterize this correlation.
Treg Cells and AS
Ankylosing spondylitis (AS) is a chronic inflammatory disease with strong genetic connections (161, 162) . Patients with AS are two to three times higher in males than females, and suffer from inflammatory spinal pain that could lead to the pathogenesis of spondyloarthritis and spinal immobility (163) . Treatment of AS by tumor necrosis factor α inhibitors seem effective, which leads to the reduction of disease progression (164) . The imbalance of Treg cells and inflammatory Th17 cells in AS patients has been previously studied but the underlying mechanism remains unclear (165, 166) . Small molecule inhibitors that promote Treg function could play a beneficial role in preventing the pathogenesis of AS (167, 168) .
Conclusion
Accumulating experimental evidence has revealed the important role of Treg cells in maintaining immune homeostasis and preventing the occurrence of autoimmune diseases. Treg cells adopt multiple molecular mechanisms to maintain their lineage stability and obtain a certain degree of functional plasticity to adapt to various inflammatory conditions. However, inflammatory factors from the local microenvironment would interfere with the stability of Treg cells and promote the development of autoimmune diseases. Therefore, exploring the molecular mechanisms behind the function of the Treg cell-lineage transcription factor FOXP3 in autoimmunity would provide insight into the understanding of the stability and plasticity of Treg cells. Treg therapy could be an important tool for treating autoimmune disease in the future. Current reports describing the effect of gender differences on Treg cells and the contributions of Treg cells to the prevalence of autoimmune diseases in females are limited. The latest findings that Treg cells are regulated by hormonal fluctuations suggest that these risk factors that may disrupt the balance between T helper and Treg cells and induce autoimmune disease include birth control pills, stress, existence or development of ovarian cysts, and overuse of products containing xenoestrogens, etc., causing hormonal imbalance. Hence, it is significantly important to take sex-based differences into consideration when exploring the role of Treg cells in human illnesses and development of Treg cell therapies for treating autoimmune diseases.
Although Treg cells are well acknowledged as a potential and promising tool for the treatment of autoimmune diseases, there is still a large gap between theory and reality. To achieve the goal of successfully and effectively using Treg cells to restore tolerance and for treating autoimmune diseases, the following important questions in Treg cell biology still need to be further addressed: 
